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Obesity is present in more than 30% of adults in the United
States and is a known risk factor for a variety of cardiovascular
problems, including coronary artery disease, atrial ﬁbrillation,
congestive heart failure, and stroke (1). Obesity is considered
to be present when there is an excess mass of adipose tissue in
the body. There is now widespread acceptance of the notion
that regional fat stores might have speciﬁc local or systemic
effects. The best-known example of a local fat depot with
a speciﬁc effect is the case of excess fat within the abdominal
cavity, which seems to contribute to insulin resistance, raised
blood pressure, and dyslipidemia. This constellation of
features is referred to as the metabolic syndrome (2).See page 128The liberation of inﬂammatory molecules from visceral fat is
thought to be a key factor in the development of the metabolic
syndrome (2). Interestingly, the adverse effects associated
with excess visceral fat are not observed or are much less
pronounced in adults with only excess subcutaneous fat (2).
The divergent properties of visceral and subcutaneous fat
highlight the importance of understanding the unique bio-
logical properties of various depots of adipose tissue.
The speciﬁc effects of localized fat pools seem tobemediated
by endocrine or paracrine actions of fat-secreted hormones
or signaling molecules (3). These hormones or molecules,
known as adipokines, include “beneﬁcial” molecules such as
adiponectin, which produces vasorelaxation and putative anti-
atherogenic effects (2,4). Adipose tissue can also secrete
“unfavorable” cytokines, including tumor necrosis factor alpha,
interleukin-6 and -8, and monocyte chemoattractant factor-1
(3,5). The elaboration of inﬂammatory cytokines is a poten-
tial pathway by which obesity could contribute to hyperten-
sion and atherosclerosis. Leptin is a fat-secreted hormone
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of this paper to disclose.important in appetite regulation, but also might increase
sympathetic tone by central mechanisms, directly stimulate
cardiac hypertrophy, and produce proinﬂammatory and
proliferative effects on smoothmuscle (6). It is provocative that
a single tissuedfat in this casedcan have seemingly opposite
effects, depending upon its location and quantity.
Observations, such as those aforementioned, have triggered
a wave of interest in the unique physiological and patho-
physiological functions of different local depots of adipose
tissue. Perivascular adipose tissue (PVAT) commonly encases
or is adherent to large vessels such as the epicardial coronary
arteries and the aorta and also many beds of smaller resistance
vessels andmicrovessels. It has been hypothesized that PVAT
might be involved in the development of cardiovascular
diseases. For example, many groups have examined the
hypothesis that epicardial fat might inﬂuence the develop-
ment of coronary atherosclerosis (7). Because obesity is
strongly associatedwith hypertension, the role of PVAT in the
regulation of blood pressure is also of substantial interest (8).
Perivascular adipose tissue has previously been reported to
block or attenuate the contractile response to vasoconstrictors
(9). This so-called “anti-contractile” effect of PVAT seems to
be mediated by paracrine mechanisms involving: 1) increased
nitric oxide bioavailability, induced in part by fat-derived
adiponectin; and 2) endothelium-independent pathways in-
volving hydrogen peroxide generation (9–11). Thus, PVAT
seems to have favorable effects that could lead to lowering
of blood pressure in vivo. However, the waters are muddied
by observations showing that the effect of “healthy PVAT” is
lost in patients who are obese (9). Adiposopathy, or “sick fat,”
is considered to be present when fat contributes to cardio-
vascular disease (12). The loss of the anti-contractile effect of
PVAT in systemic obesity was attributed to hypertrophy of
adipocytes with resultant hypoxia, inﬂammation, and oxida-
tive stress (9). One implication of that study is that there is
an interaction or signaling mechanism between PVAT and
other fat stores in the body and that PVAT might transition
between a healthy and a sick state. One group has coined the
term “vasocrine” signaling to describe the interaction between
PVAT and adjacent vasculature (13).
The function of PVAT in relation to changes in total and
regional body fat is the topic of an interesting new paper in
this issue of the Journal by Aghamohammadzadeh et al. (14).
They describe the effects of obesity and weight loss on the
regulation of vascular contraction by PVAT. They performed
studies using wire myography in isolated, endothelial-
denuded microvessels obtained from biopsy of gluteal fat in
subjects before and 6months after bariatric surgery. Segments
of the same artery were studied with and without the presence
of PVAT. Histological and biochemical studies were also
performed. Their main conclusions were that: 1) PVAT
counteracts vasoconstriction by norepinephrine in normal
weight subjects but not in obese subjects; 2) after bariatric
surgery there is normalization of the PVAT “anti-contractile”
function; and 3) the restoration of the normal protective effect
of PVAT in subjects who have lost weight is attributable to
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improved adiponectin and nitric oxide bioavailability.
The ﬁndings of this study are intriguing for several reasons.
First, a potential role of PVAT in clinically relevant disorders
such as obesity-related hypertension is of great interest (8). The
reason(s) for the high prevalence of resistant hypertension in
obese subjects remain elusive. It is noteworthy that many
studies have shown signiﬁcant reductions in blood pressure
accompanyingmodest weight loss, evenwhen patients have not
achieved a normal weight (15). These observations are remi-
niscent of those in the current study where normal vascular
regulation by PVAT was restored after weight loss, despite the
continuation of severe obesity. Perhaps regional fat pools,
particularly PVAT, respond to weight loss interventions earlier
than the larger areas of fat in the visceral and subcutaneous
compartments. The ﬁnding that there was a dramatic (app-
roximately 50%) reduction in the size of the PVAT adipocytes
at a time when there was only a moderate loss of weight and
persistent severe obesity (body mass index decreased from
approximately 52 to 38 kg/m2) supports this possibility. In
keepingwith this idea, prior studies have shown that visceral fat
volumes are reduced more than subcutaneous fat volumes early
after bariatric surgery (16). Likewise, it is well-established that
diabetes improves or even resolves in some cases, very early after
gastric bypass procedures, often before signiﬁcant weight loss
has occurred (17). This surprising effect is proposed to result
from changes in hormonal signaling from the stomach and/or
small intestine (17). The improvements in PVAT function
relatively early after gastric bypass seen in the current study are
reminiscent of the early reductions in blood pressure and the
diabetes resolution and imply that normalization of total
body fat is unlikely to be the key event necessary for other
improvements in fat-related signaling to occur.
The authors hypothesize that PVAT takes on maladaptive
or harmful characteristics when it is in a hypertrophied state
characterized by fat cells with increased volume. According
to this theory, the increased size of PVAT cells in obese
individuals creates conditions of local hypoxia that leads
to increased oxidative stress. This, in turn, accounts for
a reduction in adiponectin release. Re-establishment of the
anti-contractile effect of PVAT by exposure to superoxide
dismutase formed the basis of this conclusion.
The main limitation of this paper is the use of small vessels
isolated from subcutaneous fat, a depot not typically thought to
play a role in the metabolic syndrome or in the pathogenesis of
hypertension. Despite this limitation, the use of human tissue
and the paired studies in the same individuals before and after
gastric bypass surgery is a major strength of the current work.
The results of this study might lead us to consider interesting
and exciting possibilities for novel therapeutic approaches
involving pharmacological, genetic, or physical manipulation of
local fat beds. For example, there is tremendous interest today in
the dramatic blood pressure-lowering effects of renal artery
“denervation” (18). Is it plausible that the efﬁcacy of this proce-
dure could be attributable in some part to the effects of radio-
frequency ablationon the fat around the renal arteries or kidneys?We now need to consider, on the basis of the results of the
current study, not only the quantity of total body fat and the
quantities of regional fat but also the effect of changes in fat
stores leading to complex and dynamic interactions between
the various fat pools and the cardiovascular system.
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